Marine Biotechnology Student name: Hagay Livne I.D: 300171113 03.06.2013 www.providencecanhelp.com.

Slides:



Advertisements
Similar presentations
Test-tube or keyboard? Computation in the life sciences.
Advertisements

Richard Ekanem Biology 506 HMG November 28, 2011
Zebrafish Fukutin family proteins link the unfolded protein response with dystroglycanopathies Article Review Presented by Janet Minton 12/7/2011.
Duchenne Muscular Dystrophy and Utrophin Iona Ross BME 281 November 29, 2011.
Philip Ord Isaac Lalich DUCHENNE MUSCULAR DYSTROPHY (DMD)
Duchenne Muscular Dystrophy
Commonly referred to as DMD The disease was first described by the Neapolitan physician Giovanni Semmola in 1834 and Gaetano Conte in 1836 DMD is named.
Dystrophin and Associated Muscle Proteins Kevin Cashman Biol. 317 March 22, 2006.
Learning to swim: What fish can teach us about CMDs Jim Dowling, M.D., Ph.D. University of Michigan Congenital Muscular Dystrophy Family Conference August.
Introduction to biotechnology Haixu Tang School of Informatics.
 Stem Cells. Understandings  Specialized tissues can develop by cell differentiation in multicellular organisms.  Differentiation involves the expression.
Duchenne Muscular Dystrophy
Tiffany Hough The N-terminal region of centrosomal protein 290 (CEP290) restores vision in a zebrafish model of human blindness. Baye, L.M., Patrinostro,
(DMD) Duchenne Muscular Dystrophy. History of DMD It was first described by a french neurologist named Guillaume Benjamin Amand Duchenne in Previous.
Duchenne Muscular Dystrophy Jared Rubenstein. What Causes DMD? Caused by a mutation in a gene, called the DMD gene that can be inherited in families in.
Force of Muscle Contraction
Myopathies and their Electrodiagnosis2 Randall L. Braddom, M.D., M.S. Clinical Professor Robert Wood Johnson Medical School and the New Jersey Medical.
Lessons from the Mouse: Rett Syndrome is Potentially Treatable John Christodoulou NSW Centre for Rett Syndrome Research Western Sydney Genetics Program,
Human Genetics and the Pedigree. Section Objectives Understand how different mutations occur. Be able to identify different diseases and disorders.
Chapter 12.7 Examples of X-Linked Inheritance Patterns AP Biology Fall 2010.
Understanding Gene and Cell Therapy Approaches for DMD November
Exon Duplication and 5’ mutations in the DMD gene Nicolas Wein, PhD Flanigan Lab Center for Gene Therapy Nationwide Children’s Hospital Columbus, OH, USA.
Chapter 3 Genes in Pedigrees Mendelian Pedigree Patterns:
Zebrafish in genome research
Date:01 December 2015 Time:6:30 – 9:30 pm Location:Emory University Presentation Room 308 Speakers:Dr. John Richardson National DMD Assoc. President Got.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced Aquaporin 4 Expression in the Muscle Plasma.
Research and Development Name: Julie Long Student Number: C Course Code: DT204.2.
D uchenne M uscular D ystrophy - GENETICS - The Cause and Cure By: Chaz B.
Duchenne's Muscular Dystrophy By: Timothy Taggart & Mark Miville-Deschenes.
Gunn Abilities United Club. Muscular Dystrophy February 2014.
BY: RAHUL AND COLBY. Define terms: Gene, Allele, and Genome Gene: a heritable factor that controls a specific characteristic. Allele: one specific form.
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
Molecular Therapy - Nucleic Acids
Full length dystrophin gene Microgene for dystrophin
Duchenne Muscular Dystrophy
CRISPR Cas9 Genome Editing in Germlines
Duchenne muscular dystrophy (DMD)
Figure 2. Macrophages in dystrophic muscle in vivo and in vitro express Klotho. (A) A cross-section of 4-week-old mdx muscle labeled with antibodies to.
Implementation of a Reliable Next-Generation Sequencing Strategy for Molecular Diagnosis of Dystrophinopathies  Melissa Alame, Delphine Lacourt, Reda.
Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
The Use of Zebrafish to Understand Immunity
Volume 81, Issue 1, Pages (January 2012)
Arnd Heuser, Eva R. Plovie, Patrick T. Ellinor, Katja S
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Thomas W. Prior, Scott J. Bridgeman 
Molecular Therapy - Nucleic Acids
Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Jason.
Duchenne Muscular Dystrophy
KEY CONCEPT Entire genomes are sequenced, studied, and compared.
Volume 25, Issue 3, Pages (March 2017)
Schematic depiction of the effect of different types of Duchenne muscular dystrophy (DMD)-causing mutations on the dystrophin transcript. Schematic depiction.
Volume 18, Issue 4, Pages (April 2010)
Volume 22, Issue 4, Pages (April 2014)
Annemieke Aartsma-Rus, Anneke A. M. Janson, Wendy E
by Christopher E. Nelson, Chady H. Hakim, David G
Volume 26, Issue 6, Pages (June 2018)
Establishment of monoclonal SMN2-GFP reporter line in HEK293.
Volume 26, Issue 10, Pages (October 2018)
Volume 23, Issue 8, Pages (August 2015)
Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy  Pam M Van Ry, Ryan D.
Volume 25, Issue 3, Pages (March 2017)
TFIID binds to the TATA box through TBP
Fig. 1 Exon 44–deleted DMD patient iPSC-derived cardiomyocytes express dystrophin after CRISPR-Cas9–mediated genome editing. Exon 44–deleted DMD patient.
Volume 10, Issue 5, Pages (November 2004)
Volume 17, Issue 5, Pages (May 2009)
Fig. 2 DMD iPSC-derived cardiomyocytes express dystrophin after Cpf1-mediated genome editing by reframing. DMD iPSC-derived cardiomyocytes express dystrophin.
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Fig. 3 Correction of Dmd exon 44 deletion in mice by intramuscular AAV9 delivery of gene editing components. Correction of Dmd exon 44 deletion in mice.
Presentation transcript:

Marine Biotechnology Student name: Hagay Livne I.D:

 Giovanni Semmola in 1834 and Gaetano Conte in 1836  named after the French neurologist Guillaume Benjamin Amand Duchenne (1806–1875)  The first who did a biopsy to obtain tissue from a living patient for microscopic examination  at first the muscle forms normally but then degenerates faster than it can be repaired.  Fatal,life expectancy is around 25 years (a frequency of about 1 in 3,500 new-born males)

 caused by a mutation of the dystrophin gene at locus Xp21 (nonsense or frame shift mutations)[2]  DMD is inherited in an X-linked recessive pattern

Deutekom et al, 2003.

 The largest gene found in nature (2.4 MB)  Highly complex  Large, rod-like cytoskeletal protein  Found at the inner surface of muscle fibers  Part of the dystrophin-glycoprotein complex (DGC)  Bridges the inner cytoskeleton (F-actin) and the extra-cellular matrix

 Small, cheap and easy to grow  Penetrable for small compounds  suitable for chemical screens  Easily mutated in a large scale  Orthologs for the Dystrophin gene (DGC)  Follow the Formation of the muscle fibers

The research goal is to perform a chemical screen in zebra fish dystrophin mutants That might correct the pathology of the Muscle structure

 Fish Cultures – zebrafish mutants  sapje (stop codon in exon 4)  sapje-like (splice site mutation in exon 62)  The Prestwick chemical library  (Harvard Institute of Chemistry and Cell Biology)  Birefringence Assay  Genotyping  Histology and Immunohistochemistry  Antisense MO Injection  Western Blotting  PKA Assay

 First-Round Screen (Pooled Compounds)  Second-Round Screen Using Individual Compounds Kawahara et al, 2011.

 some fish show normal birefringence despite genotyping results Kawahara et al, 2011.

 restored muscle structure  no expression of dystrophin Kawahara et al, 2011.

 (A and B) Normal light image  (C and D) Birefringence image  (E and G) Immunostaining - anti-dystrophin antibody  (F and H) Immunostaining - anti-laminin antibody WT Dys-mut Kawahara et al,  one to two cell stage WT embryos  4 dpf

 For each chemical treatment, the percentage of affected fish is reduced (4 dpf) Kawahara et al, 2011.

 chemicals 2,3,7 proved toxic to zebrafish  the average number of surviving fish is greater in chemical 4 Kawahara et al, 2011.

Red – survivors Light Blue – control Blue – WT Green - untreated fish Kawahara et al, 2011.

 Surviving fish (30 dpf) were sectioned  skeletal muscle structure restored Kawahara et al, 2011.

Treatment with chemical 4 restored the muscle structure of these dystrophin-null fish

 A nonselective PDE5 inhibitor  Increases the levels of intercellular cAMP  Activation of cAMP-dependant PKA  Anti-inflammatory effects:  inhibition of inflammatory mediators  activation of NF-κB  PDE5 inhibitor restores mdx mouse muscle to normal  The expression, phosphorylation, and activation of PKA were examined

 Immunoblot (C)  pPKA/PKA Ratio (D)  pProteins/proteins (E) Kawahara et al, 2011.

Activated phosphorylated PKA and the activity of PKA were increased in aminophylline-treated fish Intracellular cAMP is increased with Aminophylline treatment

Kawahara et al, 2011.

 sildenafil citrate and aminophylline decreased the percentage of fish showing abnormal birefringence Kawahara et al, 2011.

 The muscle structure of aminophylline-treated dystrophin-null fish appeared normal  The activity of PKA is clearly up-regulated in aminophylline-treated dystrophin-null fish  Each of the seven chemicals increased the percentage of fish with normal birefringence  The chemical treatment did not restore dystrophin expression

 A two-tiered screening strategy  PDE inhibitors cause an increase in intracellular cAMP and/or cGMP  Mutations in the zebrafish dystrophin gene (sapje and sapje-like mutants):  good models for studies of DMD  ideally suited for use in chemical screens  easily detectable by a highly accurate birefringence assay

 The zebrafish:  small enough to be permeable to small molecules  can be assayed in large numbers  Sildenafil (viagra ©) and Tadalafil (Cialis ©) have been independently identified by others  Thousands more compounds are now available for further screening

Questions?

1. Kawahara, Genri, et al. "Drug screening in a zebrafish model of Duchenne muscular dystrophy." Proceedings of the National Academy of Sciences (2011): Koenig, Michel, et al. "Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals." Cell 50.3 (1987): Bassett, David I., and Peter D. Currie. "The zebrafish as a model for muscular dystrophy and congenital myopathy." Human molecular genetics 12.suppl 2 (2003): R265-R Van Deutekom, Judith CT, and Gert-Jan B. Van Ommen. "Advances in Duchenne muscular dystrophy gene therapy." Nature Reviews Genetics 4.10 (2003):